Literature DB >> 25615847

Reoperation rates in the surgical treatment of spinal metastases.

Nasir A Quraishi1, Ali Rajabian2, Anthony Spencer2, George Arealis2, Hossein Mehdian2, Bronek M Boszczyk2, Kimberley L Edwards3.   

Abstract

BACKGROUND CONTEXT: The surgical treatment in spinal metastases has been shown to improve function and neurologic outcome. Unplanned hospital readmissions can be costly and cause unnecessary harm.
PURPOSE: Our aim was to first analyze the reoperation rate and indications for this revision surgery in spinal metastases from an academic tertiary spinal institute and, second, to make comparisons on outcome (neurology and survival) against patients who underwent single surgery only. STUDY DESIGN/
SETTING: This was an ambispective review of all patients treated surgically over an 8-year period considering their neurologic and survival outcome data. Statistical analysis was performed using IBM SPSS 20. Because all scale values did not follow the normal distribution and significant outlier values existed, all descriptive statistics and comparisons were made using median values and the median test. Crosstabs and Pearson correlation were used to calculate differences between percentages and ordinal/nominal values. For two population proportions, the z test was used to calculate differences. The log-rank Mantel-Cox analysis was used to compare survival. PATIENT SAMPLE: During the 8 years' study period, there were 384 patients who underwent urgent surgery for spinal metastasis. Of these, 289 patients were included who had sufficient information available. There were 31 reoperations performed (10.7%; mean age, 60 years; 13 male, 18 female). Exclusion criteria included patients treated solely by radiotherapy, patients who had undergone surgery for spinal metastasis before the study period, and those who had other causes for neurologic dysfunction such as stroke. OUTCOME MEASURES: The outcomes considered in this study were revised Tokuhashi score, preoperative/postoperative Frankel scores, and survival.
METHODS: We performed an ambispective review of all patients treated surgically from our comprehensive database during the study period (October 2004 to October 2012). We reviewed all patient records on the database, including patient demographics and reoperation rates.
RESULTS: Reoperations were performed in the same admission in the majority of patients (n=20), whereas 11 patients had their second procedure in subsequent hospitalization. The reasons for their revision surgery were as follows: surgical site infection (SSI; 13 of 31 [42%]), failure of instrumentation (9 of 31 [29%]), local recurrence (5 of 31 [16%]), hematoma evacuation (2 of 31 [6%]), and others (2 of 31 [6%]).When comparing the "single surgery" and "revision surgery" groups, we found that the median preoperative and postoperative Frankel scores were similar at Grade 4 (range, 1-5) for both groups (preoperative, p=.92; postoperative, p=.87). However, 20 patients (8%) from the single surgery group and 7 (23%) from the revision group had a worse postoperative score, and this was significantly different (p=.01). No significant difference was found (p=.66) in the revised Tokuhashi score. The median number of survival days was similar (p=.719)-single surgery group: 250 days (range, 5-2,597 days) and revision group: 215 days (range, 9-1,352 days).
CONCLUSION: There was a modest reoperation rate (10.7%) in our patients treated surgically for spinal metastases over an 8-year period. Most of these were for SSI (42%), failure of instrumentation (26%), and local recurrence (16%). Patients with metastatic disease could benefit from revision surgery with comparable median survival rates but relatively poorer neurologic outcomes. This study may help to assist with informed decision making for this vulnerable patient group.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MSCC; Spinal instrument failure; Spinal instrumentation and revision surgery; Spinal oncology; Spinal reoperation; Spinal surgical site infection; Surgical treatment of spinal metastases

Mesh:

Year:  2015        PMID: 25615847     DOI: 10.1016/j.spinee.2015.01.005

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  15 in total

1.  Revision surgery and mortality following complex spine surgery: 2-year follow-up in a prospective cohort of 679 patients using the Spine AdVerse Event Severity (SAVES) system.

Authors:  Tanvir Johanning Bari; Sven Karstensen; Mathias Dahl Sørensen; Martin Gehrchen; John Street; Benny Dahl
Journal:  Spine Deform       Date:  2020-06-30

2.  Risk factors for surgical site infection after posterior fixation surgery and intraoperative radiotherapy for spinal metastases.

Authors:  Shurei Sugita; Takahiro Hozumi; Kiyofumi Yamakawa; Takahiro Goto; Taiji Kondo
Journal:  Eur Spine J       Date:  2015-07-15       Impact factor: 3.134

3.  Does surgical site infection influence neurological outcome and survival in patients undergoing surgery for metastatic spinal cord compression?

Authors:  N A Quraishi; M S Ahmed; G Arealis; B M Boszczyk; K L Edwards
Journal:  Eur Spine J       Date:  2018-10-27       Impact factor: 3.134

Review 4.  Basic concepts in metal work failure after metastatic spine tumour surgery.

Authors:  Naresh Kumar; Ravish Patel; Anshuja Charvi Wadhwa; Aravind Kumar; Helena Maria Milavec; Dhiraj Sonawane; Gurpal Singh; Lorin Michael Benneker
Journal:  Eur Spine J       Date:  2017-12-04       Impact factor: 3.134

5.  Zoledronic Acid Versus Denosumab for Prevention of Spinal Cord Compression in Advanced Cancers With Spine Metastasis: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Humaid Al Farii; Abbey Frazer; Leila Farahdel; Saud Alfayez; Michael Weber
Journal:  Global Spine J       Date:  2019-10-20

6.  Outcome of Surgical Treatment for Spinal Cord Compression in Patients With Hematological Malignancy.

Authors:  Panagiotis Tsagozis; Henrik C F Bauer
Journal:  Int J Spine Surg       Date:  2019-04-30

7.  Functional and survival outcomes in patients undergoing surgical treatment for metastatic disease of the spine.

Authors:  Vignesh K Alamanda; Myra M Robinson; Jeffrey S Kneisl; Joshua C Patt
Journal:  J Spine Surg       Date:  2018-03

Review 8.  Burden of Surgical Site Infections Associated with Select Spine Operations and Involvement of Staphylococcus aureus.

Authors:  Harshila Patel; Hanane Khoury; Douglas Girgenti; Sharon Welner; Holly Yu
Journal:  Surg Infect (Larchmt)       Date:  2016-11-30       Impact factor: 2.150

9.  Nomogram for Predicting the Postoperative Venous Thromboembolism in Spinal Metastasis Tumor: A Multicenter Retrospective Study.

Authors:  Hao-Ran Zhang; Ming-You Xu; Xiong-Gang Yang; Feng Wang; Hao Zhang; Li Yang; Rui-Qi Qiao; Ji-Kai Li; Yun-Long Zhao; Jing-Yu Zhang; Yong-Cheng Hu
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

10.  Survival Outcomes and Factors Associated with Revision Surgery for Metastatic Disease of the Spine.

Authors:  Vignesh K Alamanda; Myra M Robinson; Jeffrey S Kneisl; Leo R Spector; Joshua C Patt
Journal:  J Oncol       Date:  2018-06-25       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.